Cargando…
miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy
Background: LDH (lactate dehydrogenase), AFP (alpha-fetoprotein) and β-HCG (human chorionic gonadotropin) are used in diagnosis and follow-up of testicular germ cell cancer (TGCC) patients. Our aim was to investigate the association between levels of miR-371a-3p, miR-373-3p and miR-367-3p and clinic...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830325/ https://www.ncbi.nlm.nih.gov/pubmed/31597402 http://dx.doi.org/10.3390/cells8101221 |
_version_ | 1783465757990977536 |
---|---|
author | Rosas Plaza, Ximena van Agthoven, Ton Meijer, Coby van Vugt, Marcel A. T. M. de Jong, Steven Gietema, Jourik A. Looijenga, Leendert H. J. |
author_facet | Rosas Plaza, Ximena van Agthoven, Ton Meijer, Coby van Vugt, Marcel A. T. M. de Jong, Steven Gietema, Jourik A. Looijenga, Leendert H. J. |
author_sort | Rosas Plaza, Ximena |
collection | PubMed |
description | Background: LDH (lactate dehydrogenase), AFP (alpha-fetoprotein) and β-HCG (human chorionic gonadotropin) are used in diagnosis and follow-up of testicular germ cell cancer (TGCC) patients. Our aim was to investigate the association between levels of miR-371a-3p, miR-373-3p and miR-367-3p and clinical features in metastatic TGCC. Methods: relative levels of miR-371a-3p, miR-373-3p and miR-367-3p were evaluated in serum of metastatic TGCC patients. A prospectively included and a retrospectively selected cohort were studied (total patient number = 109). Blood samples were drawn at start of chemotherapy and during follow-up. Serum microRNA (miR) levels were determined using the ampTSmiR test. Results: at start of chemotherapy, miR-371a-3p, miR-373-3p and miR-367-3p levels were positively correlated to LDH. The median level of these miRs was higher in patients who developed a relapse after complete biochemical remission (n = 34) than in those who had complete durable remission (n = 60). Higher levels of miR-367-3p were found in patients with refractory disease (n = 15) compared to those who had complete response. miR levels decreased during the first week of chemotherapy in patients with complete response and stayed below threshold after one year of treatment. Conclusion: high miR levels at start of chemotherapy are associated with worse clinical outcome and can assist in early diagnosing of relapses. |
format | Online Article Text |
id | pubmed-6830325 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68303252019-11-20 miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy Rosas Plaza, Ximena van Agthoven, Ton Meijer, Coby van Vugt, Marcel A. T. M. de Jong, Steven Gietema, Jourik A. Looijenga, Leendert H. J. Cells Article Background: LDH (lactate dehydrogenase), AFP (alpha-fetoprotein) and β-HCG (human chorionic gonadotropin) are used in diagnosis and follow-up of testicular germ cell cancer (TGCC) patients. Our aim was to investigate the association between levels of miR-371a-3p, miR-373-3p and miR-367-3p and clinical features in metastatic TGCC. Methods: relative levels of miR-371a-3p, miR-373-3p and miR-367-3p were evaluated in serum of metastatic TGCC patients. A prospectively included and a retrospectively selected cohort were studied (total patient number = 109). Blood samples were drawn at start of chemotherapy and during follow-up. Serum microRNA (miR) levels were determined using the ampTSmiR test. Results: at start of chemotherapy, miR-371a-3p, miR-373-3p and miR-367-3p levels were positively correlated to LDH. The median level of these miRs was higher in patients who developed a relapse after complete biochemical remission (n = 34) than in those who had complete durable remission (n = 60). Higher levels of miR-367-3p were found in patients with refractory disease (n = 15) compared to those who had complete response. miR levels decreased during the first week of chemotherapy in patients with complete response and stayed below threshold after one year of treatment. Conclusion: high miR levels at start of chemotherapy are associated with worse clinical outcome and can assist in early diagnosing of relapses. MDPI 2019-10-08 /pmc/articles/PMC6830325/ /pubmed/31597402 http://dx.doi.org/10.3390/cells8101221 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rosas Plaza, Ximena van Agthoven, Ton Meijer, Coby van Vugt, Marcel A. T. M. de Jong, Steven Gietema, Jourik A. Looijenga, Leendert H. J. miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy |
title | miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy |
title_full | miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy |
title_fullStr | miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy |
title_full_unstemmed | miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy |
title_short | miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy |
title_sort | mir-371a-3p, mir-373-3p and mir-367-3p as serum biomarkers in metastatic testicular germ cell cancers before, during and after chemotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830325/ https://www.ncbi.nlm.nih.gov/pubmed/31597402 http://dx.doi.org/10.3390/cells8101221 |
work_keys_str_mv | AT rosasplazaximena mir371a3pmir3733pandmir3673passerumbiomarkersinmetastatictesticulargermcellcancersbeforeduringandafterchemotherapy AT vanagthoventon mir371a3pmir3733pandmir3673passerumbiomarkersinmetastatictesticulargermcellcancersbeforeduringandafterchemotherapy AT meijercoby mir371a3pmir3733pandmir3673passerumbiomarkersinmetastatictesticulargermcellcancersbeforeduringandafterchemotherapy AT vanvugtmarcelatm mir371a3pmir3733pandmir3673passerumbiomarkersinmetastatictesticulargermcellcancersbeforeduringandafterchemotherapy AT dejongsteven mir371a3pmir3733pandmir3673passerumbiomarkersinmetastatictesticulargermcellcancersbeforeduringandafterchemotherapy AT gietemajourika mir371a3pmir3733pandmir3673passerumbiomarkersinmetastatictesticulargermcellcancersbeforeduringandafterchemotherapy AT looijengaleenderthj mir371a3pmir3733pandmir3673passerumbiomarkersinmetastatictesticulargermcellcancersbeforeduringandafterchemotherapy |